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Background
Antibodies induced by a vaccine that will protect against
infection by HIV-1 will be heterologous, yet, little is
known on how virus evolution affects neutralization sen-
sitivity to heterologous antibodies. Therefore, experi-
ments were performed to test the sensitivity of sequential
HIV-1 primary isolates to anti-HIV-1 monoclonal anti-
bodies (mAbs) and to analyze changes in the neutraliza-
tion epitopes.
Methods
Anti-HIV-1 mAbs directed at epitopes in the gp120 enve-
lope (anti-V2, anti-V3, anti-CD4bd, and anti-carbohy-
drate) were tested in the TZM-bl neutralization assay with
sequential primary HIV-1 isolates obtained from four
HIV-1 infected drug naive individuals. The gp120
sequences from the sequential viruses were analyzed to
identify changes in the neutralization sensitive epitopes.
Results
Overall, primary viruses collected from patients at first
visit were all resistant to neutralization by anti-HIV-1
mAbs. Three of the four patients' sequential viruses
evolved with increased sensitivity to neutralization by
anti-V3 mAbs. In particular, virus collected from a patient
31 months after the first visit became more sensitive to
neutralization by anti-V2, anti-V3, and anti-CD4bd mAbs.
Another patient's later time point virus (collected after 11
months) evolved with increased sensitivity to five of six
anti-V3 mAbs. The third patient's later time point virus
(collected after 36 months) exhibited increased, but weak
sensitivity to neutralization by anti-V3 mAbs. Anti-V3
mAbs exhibited the broadest and most potent neutraliz-
ing capacity to the evolving viruses over time. Sequence
analysis of the envelope regions revealed amino acid
changes occurring mainly outside of the mAb core
epitope. Only few or no changes were noted in the V3
loop sequences.
Conclusion
This study demonstrates that HIV-1 viruses evolve with
changes that increase neutralization sensitivity to some
mAbs and that these changes occur outside the core neu-
tralization sensitive epitope. Changes that cause increase
in neutralization sensitivity may be useful in designing
vaccines that may induce potent protective antibodies.
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